NO20075258L - Vannfrie krystallinske former av N-(1-(2-etoksyetyl)-5-(N-etyl-N-metylamino)-7-(4-metylpyndin-2-yl-amino)-1H-pyrazolo(4,3-d)pyrimidin-3-carbonyl)metansulfonamid - Google Patents

Vannfrie krystallinske former av N-(1-(2-etoksyetyl)-5-(N-etyl-N-metylamino)-7-(4-metylpyndin-2-yl-amino)-1H-pyrazolo(4,3-d)pyrimidin-3-carbonyl)metansulfonamid

Info

Publication number: NO20075258L
Authority: NO; Norway
Prior art keywords: methanesulfonamide; methylpyridin; pyrazolo; ethoxyethyl; methylamino
Prior art date: 2005-05-12

Application number

NO20075258A

Other languages

English (en)

Norwegian (no)

Inventor

David Andrew Entwistle

Peter Wallance Marshall

Stefan Colin Taylor

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-12

Filing date

2007-10-12

Publication date

2007-11-15

2007-10-12 Application filed by Pfizer filed Critical Pfizer

2007-11-15 Publication of NO20075258L publication Critical patent/NO20075258L/no

Links

-1 2-ethoxyethyl Chemical group 0.000 title 4
ZUHZNKJIJDAJFD-UHFFFAOYSA-N 1-(2-ethoxyethyl)-5-[ethyl(methyl)amino]-7-[(4-methylpyridin-2-yl)amino]-n-methylsulfonylpyrazolo[4,3-d]pyrimidine-3-carboxamide Chemical compound C=12N(CCOCC)N=C(C(=O)NS(C)(=O)=O)C2=NC(N(C)CC)=NC=1NC1=CC(C)=CC=N1 ZUHZNKJIJDAJFD-UHFFFAOYSA-N 0.000 abstract 2
102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Psychology (AREA)
Pregnancy & Childbirth (AREA)

NO20075258A 2005-05-12 2007-10-12 Vannfrie krystallinske former av N-(1-(2-etoksyetyl)-5-(N-etyl-N-metylamino)-7-(4-metylpyndin-2-yl-amino)-1H-pyrazolo(4,3-d)pyrimidin-3-carbonyl)metansulfonamid NO20075258L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US68044505P	2005-05-12	2005-05-12
US68171105P	2005-05-17	2005-05-17
PCT/IB2006/001233 WO2006120552A2 (fr)	2005-05-12	2006-05-03	Formes cristallines anhydres de n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide

Publications (1)

Publication Number	Publication Date
NO20075258L true NO20075258L (no)	2007-11-15

Family

ID=37106941

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20075258A NO20075258L (no)	2005-05-12	2007-10-12	Vannfrie krystallinske former av N-(1-(2-etoksyetyl)-5-(N-etyl-N-metylamino)-7-(4-metylpyndin-2-yl-amino)-1H-pyrazolo(4,3-d)pyrimidin-3-carbonyl)metansulfonamid

Country Status (23)

Country	Link
US (3)	US8227475B2 (fr)
EP (1)	EP1881985B1 (fr)
JP (2)	JP4271695B2 (fr)
KR (1)	KR100939890B1 (fr)
AT (1)	ATE493413T1 (fr)
AU (1)	AU2006245416B2 (fr)
BR (1)	BRPI0609225A2 (fr)
CA (1)	CA2608018C (fr)
CR (1)	CR9505A (fr)
CY (1)	CY1111171T1 (fr)
DE (1)	DE602006019231D1 (fr)
DK (1)	DK1881985T3 (fr)
EA (1)	EA012577B1 (fr)
IL (1)	IL186693A (fr)
MA (1)	MA29447B1 (fr)
MX (1)	MX2007013215A (fr)
NO (1)	NO20075258L (fr)
NZ (1)	NZ564187A (fr)
PL (1)	PL1881985T3 (fr)
PT (1)	PT1881985E (fr)
TN (1)	TNSN07414A1 (fr)
TW (1)	TWI380986B (fr)
WO (1)	WO2006120552A2 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7676953B2 (en) *	2006-12-29	2010-03-16	Signature Control Systems, Inc.	Calibration and metering methods for wood kiln moisture measurement
WO2009050554A2 (fr) *	2007-10-19	2009-04-23	Pfizer Inc.	Traitement de troubles du système nerveux central
WO2012048330A2 (fr) *	2010-10-08	2012-04-12	The Mclean Hospital Corporation	Traitement de maladie neuromotrice
CA2830027C (fr)	2011-03-31	2016-04-26	Pfizer Inc.	Nouvelles pyridones bicycliques
AP2013007253A0 (en)	2011-04-21	2013-11-30	Origenis Gmbh	Pyrazolo [4,3-D] pyrimidines useful as kinase inhibitors
WO2012172449A1 (fr)	2011-06-13	2012-12-20	Pfizer Inc.	Lactames convenant comme inhibiteurs des bêta-sécrétases
CN102952138B (zh) *	2011-08-17	2016-07-06	上海特化医药科技有限公司	一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
JP6043355B2 (ja)	2011-08-31	2016-12-14	ファイザー・インク	ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2013164730A1 (fr)	2012-05-04	2013-11-07	Pfizer Inc.	Composés d'hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par des hétérocycliques à titre d'inhibiteurs d'app, bace1 et bace2
EP2897964A1 (fr)	2012-09-20	2015-07-29	Pfizer Inc.	Composés de hexahydropyrano [3,4-d][1,3]thiazin-2-amine substitués par alkyle
UA110688C2 (uk)	2012-09-21	2016-01-25	Пфайзер Інк.	Біциклічні піридинони
WO2014060112A1 (fr)	2012-10-19	2014-04-24	Origenis Gmbh	Pyrazolo[4,3-d]pyrimidines utiles en tant qu'inhibiteurs de kinases
MX2015005004A (es) *	2012-10-23	2015-07-17	Pfizer	Uso de un compuesto de pirazolo[4,3-d]pirimidina tetrasubstituida para tratar la nefropatia diabetica.
EP2931731A1 (fr)	2012-12-11	2015-10-21	Pfizer Inc.	Composés d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
US9403846B2 (en)	2012-12-19	2016-08-02	Pfizer Inc.	Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2956458B1 (fr)	2013-02-13	2017-08-09	Pfizer Inc	Composés hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par un hétéroaryle
US9233981B1 (en)	2013-02-15	2016-01-12	Pfizer Inc.	Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
BR112015019276A2 (pt)	2013-02-19	2017-07-18	Pfizer	compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
JP6425717B2 (ja)	2013-10-04	2018-11-21	ファイザー・インク	ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン
AP2016009465A0 (en)	2014-04-01	2016-09-30	Pfizer	Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
CN106459088A (zh)	2014-04-10	2017-02-22	辉瑞公司	2‑氨基‑6‑甲基‑4，4a，5，6‑四氢吡喃并[3，4‑d][1，3]噻嗪‑8a(8H)‑基‑1，3‑噻唑‑4‑基酰胺
WO2016012896A1 (fr)	2014-07-24	2016-01-28	Pfizer Inc.	Composés de pyrazolopyrimidine
MD20170011A2 (ro)	2014-08-06	2017-08-31	Pfizer Inc.	Compuşi imidazopiridazinici
MX368391B (es)	2015-02-03	2019-09-30	Pfizer	Ciclopropabenzofuranil-piridopirazindionas novedosas.
CN107787322B (zh)	2015-06-17	2023-07-07	辉瑞大药厂	三环化合物以及它们作为磷酸二酯酶抑制剂的用途
JP2018534251A (ja)	2015-09-24	2018-11-22	ファイザー・インク	Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
WO2017051303A1 (fr)	2015-09-24	2017-03-30	Pfizer Inc.	Dérivés de tétrahydropyrano[3,4-d] [1,3]oxazine et leur utilisation en tant qu'inhibiteurs de bace
JP2018531923A (ja)	2015-09-24	2018-11-01	ファイザー・インク	Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド
CN113332292A (zh)	2016-02-23	2021-09-03	辉瑞公司	6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物
PT3478679T (pt)	2016-07-01	2021-06-30	Pfizer	Derivados de 5,7-dihidro-pirrolo-piridina para o tratamento de doenças neurológicas e neurodegenerativas
IL271290B2 (en)	2017-06-22	2023-11-01	Pfizer	Dihydro-pyrrolo-pyridine derivatives
PT3768669T (pt)	2018-03-23	2023-04-24	Pfizer	Derivados de piperazina azaspiro
US12144815B2 (en)	2021-02-23	2024-11-19	Hoth Therapeutics, Inc.	Use of aprepitant for treating Alzheimer's disease
WO2024118524A1 (fr)	2022-11-28	2024-06-06	Cerevel Therapeutics, Llc	Composés d'azaindole et leur utilisation en tant qu'inhibiteurs de phosphodiestérase
WO2025145091A1 (fr)	2023-12-29	2025-07-03	Pfizer Inc.	Formes cristallines d'un modulateur muscarinique m4 du récepteur et méthodes de traitement de maladies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9119704D0 (en)	1991-09-14	1991-10-30	Pfizer Ltd	Therapeutic agents
GB9121028D0 (en)	1991-10-03	1991-11-13	Pfizer Ltd	Therapeutic agents
GB9126260D0 (en)	1991-12-11	1992-02-12	Pfizer Ltd	Therapeutic agents
GB9213623D0 (en)	1992-06-26	1992-08-12	Pfizer Ltd	Therapeutic agents
GB9218322D0 (en)	1992-08-28	1992-10-14	Pfizer Ltd	Therapeutic agents
GB9401090D0 (en)	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
US6723719B1 (en)	1997-04-25	2004-04-20	Pfizer Inc	Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
CA2395558C (fr)	1997-11-12	2007-07-17	Bayer Aktiengesellschaft	Imidazotriazinones a substitution 2-phenyle utilisees comme inhibiteurs des phosphodiesterases
RS50011B (sr)	1998-04-20	2008-09-29	Pfizer Inc.,	Derivati piridin-3-karboksilne kiseline i njihova upotreba kao intermedijera
BR9915532A (pt)	1998-10-23	2001-08-14	Pfizer	Inibidores de cgmp pde5 de pirazolopirimidinona para tratamento da disfunção sexual
DE19942474A1 (de)	1999-09-06	2001-03-15	Merck Patent Gmbh	Pyrazolo[4,3-d]pyrimidine
TWI265925B (en)	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
HK1049834A1 (zh)	1999-10-11	2003-05-30	辉瑞大药厂	用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物
DE10031584A1 (de)	2000-06-29	2002-01-10	Merck Patent Gmbh	5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
PT1305314E (pt)	2000-07-28	2005-04-29	Pfizer	Agente terapeutico cristalino
ATE478872T1 (de) *	2002-03-28	2010-09-15	Ustav Ex Botan Av Cr V V I I O	Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
OA13050A (en)	2003-04-29	2006-11-10	Pfizer Ltd	5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
US7572799B2 (en) *	2003-11-24	2009-08-11	Pfizer Inc	Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327323D0 (en)	2003-11-24	2003-12-31	Pfizer Ltd	Novel pharmaceuticals
GB0327319D0 (en) *	2003-11-24	2003-12-24	Pfizer Ltd	Novel pharmaceuticals
CA2562251C (fr)	2004-04-07	2009-04-28	Pfizer Inc.	Pyrazolo'4,3-d pyrimidines
EP1809632A2 (fr)	2004-10-28	2007-07-25	Pharmacia & Upjohn Company LLC	Derives de pyrazolo [4,3-d] pyrimidine utiles comme inhibiteurs de pde-5

2006
- 2006-05-03 CA CA2608018A patent/CA2608018C/fr not_active Expired - Fee Related
- 2006-05-03 WO PCT/IB2006/001233 patent/WO2006120552A2/fr not_active Ceased
- 2006-05-03 AU AU2006245416A patent/AU2006245416B2/en not_active Ceased
- 2006-05-03 AT AT06744689T patent/ATE493413T1/de active
- 2006-05-03 DE DE602006019231T patent/DE602006019231D1/de not_active Expired - Lifetime
- 2006-05-03 KR KR1020077026098A patent/KR100939890B1/ko not_active Expired - Fee Related
- 2006-05-03 MX MX2007013215A patent/MX2007013215A/es active IP Right Grant
- 2006-05-03 PL PL06744689T patent/PL1881985T3/pl unknown
- 2006-05-03 NZ NZ564187A patent/NZ564187A/en not_active IP Right Cessation
- 2006-05-03 EA EA200702217A patent/EA012577B1/ru not_active IP Right Cessation
- 2006-05-03 EP EP06744689A patent/EP1881985B1/fr not_active Expired - Lifetime
- 2006-05-03 US US11/913,091 patent/US8227475B2/en not_active Expired - Fee Related
- 2006-05-03 BR BRPI0609225-0A patent/BRPI0609225A2/pt not_active IP Right Cessation
- 2006-05-03 DK DK06744689.8T patent/DK1881985T3/da active
- 2006-05-03 PT PT06744689T patent/PT1881985E/pt unknown
- 2006-05-11 TW TW095116704A patent/TWI380986B/zh not_active IP Right Cessation
- 2006-05-11 JP JP2006132110A patent/JP4271695B2/ja not_active Expired - Fee Related
2007
- 2007-10-12 NO NO20075258A patent/NO20075258L/no not_active Application Discontinuation
- 2007-10-16 IL IL186693A patent/IL186693A/en not_active IP Right Cessation
- 2007-11-09 TN TNP2007000414A patent/TNSN07414A1/fr unknown
- 2007-11-09 CR CR9505A patent/CR9505A/es unknown
- 2007-11-12 MA MA30362A patent/MA29447B1/fr unknown
2009
- 2009-01-07 JP JP2009001627A patent/JP4996631B2/ja not_active Expired - Fee Related
2011
- 2011-02-08 CY CY20111100142T patent/CY1111171T1/el unknown
2012
- 2012-04-27 US US13/457,886 patent/US8796287B2/en not_active Expired - Fee Related
- 2012-04-27 US US13/457,969 patent/US8796288B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ATE493413T1 (de)	2011-01-15
US20080194591A1 (en)	2008-08-14
US8796287B2 (en)	2014-08-05
TWI380986B (zh)	2013-01-01
KR20080004593A (ko)	2008-01-09
DK1881985T3 (da)	2011-02-14
TNSN07414A1 (fr)	2009-03-17
EP1881985B1 (fr)	2010-12-29
EA012577B1 (ru)	2009-10-30
JP4271695B2 (ja)	2009-06-03
WO2006120552A3 (fr)	2007-01-18
US8227475B2 (en)	2012-07-24
US8796288B2 (en)	2014-08-05
NZ564187A (en)	2010-03-26
JP4996631B2 (ja)	2012-08-08
MX2007013215A (es)	2007-12-12
BRPI0609225A2 (pt)	2010-03-09
CR9505A (es)	2008-01-02
JP2006316058A (ja)	2006-11-24
KR100939890B1 (ko)	2010-01-29
CA2608018A1 (fr)	2006-11-16
CA2608018C (fr)	2010-07-13
JP2009137987A (ja)	2009-06-25
DE602006019231D1 (en)	2011-02-10
PL1881985T3 (pl)	2011-05-31
AU2006245416B2 (en)	2012-02-23
PT1881985E (pt)	2011-02-01
TW200716641A (en)	2007-05-01
IL186693A (en)	2012-07-31
US20120208830A1 (en)	2012-08-16
CY1111171T1 (el)	2015-06-11
AU2006245416A1 (en)	2006-11-16
US20120214827A1 (en)	2012-08-23
WO2006120552A2 (fr)	2006-11-16
EP1881985A2 (fr)	2008-01-30
IL186693A0 (en)	2008-02-09
MA29447B1 (fr)	2008-05-02
HK1116485A1 (en)	2008-12-24
EA200702217A1 (ru)	2008-04-28

Legal Events

Date	Code	Title	Description
2009-12-21	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20075258L (no)	2007-11-15	Vannfrie krystallinske former av N-(1-(2-etoksyetyl)-5-(N-etyl-N-metylamino)-7-(4-metylpyndin-2-yl-amino)-1H-pyrazolo(4,3-d)pyrimidin-3-carbonyl)metansulfonamid
ATE430747T1 (de)	2009-05-15	2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
EA200500203A1 (ru)	2005-08-25	Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
WO2007067506A3 (fr)	2007-08-16	Inhibiteurs d'erbb kinase de 2-pyrimidinyl-pyrazolopyridine
PT1379520E (pt)	2006-08-31	Antagonistas (nao-aril)-heterociclicos n-substituidos de nmda/nr2b
WO2005110410A3 (fr)	2007-03-29	Inhibiteurs de kinases en tant qu'agents therapeutiques
MXPA05012025A (es)	2006-02-03	Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
WO2007002635A3 (fr)	2007-03-29	Antagonistes cycliques a liaison c du recepteur p2y1, utiles pour traiter des etats pathologiques thrombotiques
NO20071915L (no)	2007-05-18	Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
NO20081554L (no)	2008-06-02	Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
NO20053470L (no)	2005-09-02	Triazolopyridaziner som proteinkinase-inhibitorer
WO2007059257A3 (fr)	2007-08-23	Inhibiteurs erbb
WO2003095455A3 (fr)	2003-12-24	Composes therapeutiques
EA200501928A1 (ru)	2006-12-29	Пирролодигидроизохинолины как ингибиторы pde10
UA83091C2 (en)	2008-06-10	Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
WO2006047528A3 (fr)	2007-03-01	Pyrazolobenzamides et leurs derives en tant qu'inhibiteurs du facteur xa
EA200801199A1 (ru)	2008-08-29	Ингибиторы киназы
WO2005032490A3 (fr)	2005-07-28	Diamines cycliques et derives comme inhibiteurs du facteur xa
WO2004067703A3 (fr)	2004-11-04	Antagonistes 5ht7 et agonistes inverses
NO20070550L (no)	2007-03-26	Fremgangsmate for fremstilling av pyrrolotriazinforbindelser
WO2007120333A3 (fr)	2008-01-10	Inhibiteurs de kinase tétracycliques
WO2004072029A3 (fr)	2004-12-16	Compositions utiles en tant qu'inhibiteurs de proteine kinases
WO2007068728A3 (fr)	2007-09-27	Pyrrolopyridinones n-substituees actives en tant qu'inhibiteurs de kinase
TW200738625A (en)	2007-10-16	3-Amino-1-arylpropyl indoles and aza-substituted indoles
WO2006124865A3 (fr)	2007-01-11	Biaryles utiles en tant que modulateurs des canaux ioniques